GlassScriptPhysician profile
Nithin Reddy
NPI 1184288847
$7,057.70
in general payments reported to CMS, 2019-2025
22 companies · $3,120 in 2025
The $3,120 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,092 · 2024: $2,845 · 2025: $3,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,959 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,958.70 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,626.77 | 2023-2025 | |
| Dermavant Sciences, INC. | $694.33 | 2023-2024 | Vtama |
| Lilly USA, LLC | $677.12 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $523.37 | 2023-2025 | |
| Janssen Biotech, INC. | $442.29 | 2024-2025 | Tremfya |
| Incyte Corporation | $387.35 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $347.14 | 2024-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $345.53 | 2024-2025 | Nemluvio, Aklief |
| Pfizer INC. | $339.26 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $294.91 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $263.76 | 2023-2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.63 | 2023 | |
| Ucb, INC. | $195.58 | 2023-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $181.68 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $169.58 | 2024-2025 | Dupixent, Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $106.79 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.71 | 2025 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $66.14 | 2024-2025 | |
| Sandoz INC. | $21.49 | 2024 | Hyrimoz |
| Fidia Pharma USA INC. | $21.46 | 2024 | |
| Organon LLC | $20.87 | 2025 | |
| Verrica Pharmaceuticals INC. | $17.94 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nithin Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.